Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open Label
Phase 3Active 1 views this week 0 watching⚡ Active
Interest: 44/100
44
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Hormone Sensitive Prostate Cancer
Conditions
Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate
Trial Timeline
Dec 17, 2014 → Sep 19, 2026
NCT ID
NCT02319837About Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open Label
Enzalutamide + Placebo (No longer applicable in Open Label study period) + Leuprolide Open Label is a phase 3 stage product being developed by Astellas Pharma for Hormone Sensitive Prostate Cancer. The current trial status is active. This product is registered under clinical trial identifier NCT02319837. Target conditions include Hormone Sensitive Prostate Cancer, Prostate Cancer, Cancer of the Prostate.
What happened to similar drugs?
9 of 20 similar drugs in Hormone Sensitive Prostate Cancer were approved
Approved (9) Terminated (2) Active (11)
Hype Score Breakdown
Clinical
17
Activity
12
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT02319837 | Phase 3 | Active |
Competing Products
20 competing products in Hormone Sensitive Prostate Cancer